The Annual General Meeting of 2019 decided that the Nomination Committee would be appointed as follows: “The Chairman of the Board shall convene the three largest shareholders in the Company, who each shall elect representative to be a member of the Nomination Committee together with the Chairman of the Board. In the establishment of the Nomination Committee, the ownership ratios as of June 30, 2019 shall determine the largest shareholders in terms of voting rights. The representative of the largest shareholder in the Nomination Committee at that time shall be the Chairman of the Nomination committee. If any of the three largest shareholders waives their right to appoint a member of the Nomination Committee, the next largest shareholder shall be allowed to appoint a member of the Nomination Committee.
The Nomination Committee has been formed in accordance with the decision of the Annual General Meeting and consists of, in addition to the Chairman of Infant Bacterial Therapeutics AB's Board of Directors, Peter Rothschild, Per-Erik Andersson, representative of the company's largest shareholder Annwall & Rothschild Investments AB, Jannis Kitsakis, representative of the company's next largest shareholder Fourth AP-Fonden and Sebastian Jahreskog, who via direct and indirect ownership is the company's third largest shareholder. All members of the Nomination Committee, except Peter Rothschild, are independent in relation to the company and company management.
The Nomination Committee has appointed Per-Erik Andersson, as the chairman of the Nomination Committee.
Shareholders who wish to submit proposals to the Nomination Committee before the Annual General Meeting on May 11, 2020 can do so by e-mail to pererik.andersson@pealaw.se, or by phone
070-537 9892 by April 10, 2020.
About Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB (publ) is a pharmaceutical company with a product in clinical stage with a vision to develop drugs influencing the infant microbiome, and thereby prevent or treat rare diseases affecting infants.
IBT is currently developing the drug candidate IBP-9414, for the prevention of necrotizing enterocolitis (“NEC”) and improvement of so called feeding tolerance in premature infants. IBP-9414 contains the active compound Lactobacillus reuteri, which is a human bacterial strain naturally present in breast milk. The product portfolio also includes another project, IBP-1016, for the treatment of gastroschisis, a severe and rare disease affecting infants. By developing these drugs, IBT has the potential to fulfil unmet needs for diseases where there are currently no prevention or treatment therapies available.
Infant Bacterial Therapeutics AB (“IBT”) is a public company domiciled in Stockholm. The company’s class B-shares shares are listed on Nasdaq Stockholm, Mid-cap (IBT B).
For additional information please contact
Staffan Strömberg, CEO
Daniel Mackey, CFO
Infant Bacterial Therapeutics AB
Bryggargatan 10
111 21 Stockholm
Phone: +46 70 670 1226
info@ibtherapeutics.com
www.ibtherapeutics.com